Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoting Fei

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|April 25, 2024
Recent Progress in DNA Damage Response-Targeting PROTAC DegradersBinbin Cheng, Xiaoting Fei, Zongbao Ding, et al.
Journal of Medicinal Chemistry|July 21, 2023
Discovery of Novel d-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for Targeted Cancer ImmunotherapyZongbao Ding, Shuanghu Wang, Yaru Shi, et al.
European Journal of Medicinal Chemistry|July 3, 2024
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009-2024)Binbin Cheng, Xianshi Ma, Yingxing Zhou, et al.
European Journal of Medicinal Chemistry|January 11, 2024
HDAC-targeting epigenetic modulators for cancer immunotherapyBinbin Cheng, Wei Pan, Yao Xiao, et al.
Journal of Medicinal Chemistry|April 8, 2024
Discovery of Novel Heterotricyclic Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate Cancer ImmunotherapyBinbin Cheng, Yaru Shi, Chuxiao Shao, et al.
Journal of Medicinal Chemistry|May 15, 2024
Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual ImmunotherapyShuanghu Wang, Zhihua Kong, Yaru Shi, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|April 25, 2024
Recent Progress in DNA Damage Response-Targeting PROTAC DegradersBinbin Cheng, Xiaoting Fei, Zongbao Ding, et al.
Journal of Medicinal Chemistry|July 21, 2023
Discovery of Novel d-(+)-Biotin-Conjugated Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors for Targeted Cancer ImmunotherapyZongbao Ding, Shuanghu Wang, Yaru Shi, et al.
European Journal of Medicinal Chemistry|July 3, 2024
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009-2024)Binbin Cheng, Xianshi Ma, Yingxing Zhou, et al.
European Journal of Medicinal Chemistry|January 11, 2024
HDAC-targeting epigenetic modulators for cancer immunotherapyBinbin Cheng, Wei Pan, Yao Xiao, et al.
Journal of Medicinal Chemistry|April 8, 2024
Discovery of Novel Heterotricyclic Compounds as DNA-Dependent Protein Kinase (DNA-PK) Inhibitors with Enhanced Chemosensitivity, Oral Bioavailability, and the Ability to Potentiate Cancer ImmunotherapyBinbin Cheng, Yaru Shi, Chuxiao Shao, et al.
Journal of Medicinal Chemistry|May 15, 2024
Discovery of Small and Bifunctional Molecules Targeting PD-L1/CD73 for Cancer Dual ImmunotherapyShuanghu Wang, Zhihua Kong, Yaru Shi, et al.
Pageof 1